Carotenuto, Pietro http://orcid.org/0000-0002-6622-183X
Amato, Francesco
Lampis, Andrea
Rae, Colin http://orcid.org/0000-0003-4432-6670
Hedayat, Somaieh
Previdi, Maria C.
Zito, Domenico
Raj, Maya
Guzzardo, Vincenza
Sclafani, Francesco
Lanese, Andrea
Parisi, Claudia
Vicentini, Caterina
Said-Huntingford, Ian
Hahne, Jens C.
Hallsworth, Albert
Kirkin, Vladimir
Young, Kate
Begum, Ruwaida
Wotherspoon, Andrew
Kouvelakis, Kyriakos
Azevedo, Sergio Xavier
Michalarea, Vasiliki
Upstill-Goddard, Rosie http://orcid.org/0000-0002-2666-0934
Rao, Sheela
Watkins, David
Starling, Naureen
Sadanandam, Anguraj http://orcid.org/0000-0001-8485-5150
Chang, David K. http://orcid.org/0000-0002-4821-3078
Biankin, Andrew V. http://orcid.org/0000-0002-0362-5597
Jamieson, Nigel B. http://orcid.org/0000-0002-9552-4725
Scarpa, Aldo http://orcid.org/0000-0003-1678-739X
Cunningham, David http://orcid.org/0000-0001-5158-1069
Chau, Ian http://orcid.org/0000-0003-0286-8703
Workman, Paul http://orcid.org/0000-0003-1659-3034
Fassan, Matteo http://orcid.org/0000-0001-6515-5482
Valeri, Nicola http://orcid.org/0000-0002-5426-5683
Braconi, Chiara http://orcid.org/0000-0003-4835-1259
Article History
Received: 6 October 2020
Accepted: 29 October 2021
First Online: 18 November 2021
Competing interests
: F.S. has a consultancy role with Bayer; has received research funding from AstraZeneca, Bayer, BMS, Roche; and travel grants from Bayer and Lilly. N.S. has received research funding from AstraZeneca, BMS, Pfizer; honoraria from Eli Lilly, Merck Serono, MSD Oncology, Pierre Fabre, Servier; travel/accommodation from AstraZeneca, BMS, Eli Lilly, Merck, Roche; and has had advisory roles with Pfizer, AstraZeneca, Servier. D.K.C. received research funding from Celgene, AstraZeneca, MSD and Immodulon, and honoraria from Celgene. D.C. has received funding from Amgen, Sanofi, Merrimack, AstraZeneca, Celgene, MedImmune, Bayer, 4SC, Clovis, Eli Lilly, Janssen, Merck; and has an advisory role with OVIBIO. M.F. has received grants from Astellas Pharma and QED Therapeutics; and has advisory roles with Astellas Pharma, Tesaro, and Diaceutics. F.S. received funding from Amal Therapeutics, Bayer, BMS, Dragonfly Therapeutics, Amgen (inst), AstraZeneca (Inst), Bayer (Inst), BMS (Inst), Roche (Inst), Sanofi (Inst), Bayer, Lilly and is Co-Chair EORTC Colon Cancer Task Force. N.V. received honoraria or travel accommodation from Merck Serono, Pfizer, Bayer, Eli-Lilly, and Menarini Silicon Biosystems. P.W. advises and received grants from Astex Pharmaceuticals; advises and owns stock in Nextechinvest; is employed and owns stock in Storm Therapeutics; advises CV6 Therapeutics, Black Diamond Therapeutics, and Vividion Therapeutics; received grants from Vernalis and Merck, and owns stock in Chroma Therapeutics. C.B. received honoraria from Incyte. All other authors declare no competing interests.